News >

FDA Grants Priority Review to Adjuvant Nivolumab in Melanoma

Jason Harris
Published: Wednesday, Oct 18, 2017

Murdo Gordon, BMS executive vice president and chief commercial officer

Murdo Gordon
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication